Posts

FDA declines to approve Zealand Pharma’s hypoglycaemia ...

The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaem...

Purespring secures $105m to start Phase I/II trial of I...

Purespring Therapeutics has raised $105m in a Series B funding round which will ...

Clinical Dose Companies in Contract Manufacturing for t...

Discover the leading Clinical Dose Companies in Contract Manufacturing. Download...

Anima Biotech’s machine learning programme ‘reveals new...

The company employs machine learning to uncover disease mechanisms at the mRNA l...

MSD ventures into fibroblast therapies with $1.9bn deal...

The deal allows MSD to license one or more therapies against inflammatory diseas...

Editas Sells Rights to a Licensing Agreement in a $57 M...

In a recent move, Editas sold part of these rights to DRI Healthcare’s subsidiar...

mRNA licensing agreements double with million-dollar deals

mRNA-based vaccines, which instruct cells to produce proteins that can prevent o...

Neuvivo makes bid to enter ALS arena with immunotherapy...

NP001 is designed to tackle the neurodegenerative disease through an immunologic...

EMA starts review into hair loss drugs about potential ...

The safety review was requested by the French medicines agency, citing new safet...

Oncolytics targets accelerated approval for oncolytic v...

The company intends to start a registrational Phase II trial of pelareorep and c...

Activist investor Starboard forges $1bn stake in Pfizer...

US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker strugg...

ProductLife boosts drug development with IntiQuan acqui...

ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm ...

Health Canada approves Telix’s Illuccix label expansion

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix f...

OnKure and Reneo Pharmaceuticals complete merger

OnKure has announced the successful completion of its merger with Reneo Pharmace...

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with...

Teva and mAbxience partner to develop biosimilar candid...

Teva Pharmaceuticals International and mAbxience have entered into a worldwide l...